Pranlukast: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
fixed SMILES
Citation bot (talk | contribs)
Bots
4,914,755 edits
m Alter: last. Add: pages, issue, volume. | You can use this bot yourself. Report bugs here.| Activated by User:Headbomb
Line 47: Line 47:
Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of [[bronchospasm]] caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered [[allergen]]s.<ref name="SinghTandon2013">{{cite journal|last1=Singh|first1=Rakesh Kumar|last2=Tandon|first2=Ruchi|last3=Dastidar|first3=Sunanda Ghosh|last4=Ray|first4=Abhijit|title=A review on leukotrienes and their receptors with reference to asthma|journal=Journal of Asthma|volume=50|issue=9|year=2013|pages=922–931|issn=0277-0903|doi=10.3109/02770903.2013.823447|pmid=23859232}}</ref>
Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of [[bronchospasm]] caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered [[allergen]]s.<ref name="SinghTandon2013">{{cite journal|last1=Singh|first1=Rakesh Kumar|last2=Tandon|first2=Ruchi|last3=Dastidar|first3=Sunanda Ghosh|last4=Ray|first4=Abhijit|title=A review on leukotrienes and their receptors with reference to asthma|journal=Journal of Asthma|volume=50|issue=9|year=2013|pages=922–931|issn=0277-0903|doi=10.3109/02770903.2013.823447|pmid=23859232}}</ref>


Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled [[Long acting beta-adrenoceptor agonist|long-]] and/or short-acting [[Beta2-adrenergic receptor agonist|beta-agonist]]s. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models <ref name="Mishra A 2018">{{cite journal|last= Mishra A et al.,|title=An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy.|journal=EMBO Molecular Medicine|date=2018|doi=10.15252/emmm.201708038}}</ref>.
Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled [[Long acting beta-adrenoceptor agonist|long-]] and/or short-acting [[Beta2-adrenergic receptor agonist|beta-agonist]]s. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models <ref name="Mishra A 2018">{{cite journal|last= Mishra A et al.|title=An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy.|journal=EMBO Molecular Medicine|volume=10|issue=4|pages=e8038|date=2018|doi=10.15252/emmm.201708038}}</ref>.
==References==
==References==


Revision as of 17:41, 5 July 2019

Pranlukast
Clinical data
Trade namesOnon (オノン)
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Pharmacokinetic data
MetabolismHepatic (mainly CYP3A4)[1]
Elimination half-life1.5 hours[1]
Identifiers
  • N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.236.084 Edit this at Wikidata
Chemical and physical data
FormulaC27H23N5O4
Molar mass481.503 g/mol g·mol−1
3D model (JSmol)
  • O=C(Nc2cccc3c(=O)cc(c1nn[nH]n1)oc23)c5ccc(OCCCCc4ccccc4)cc5
  • InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) checkY
  • Key:NBQKINXMPLXUET-UHFFFAOYSA-N checkY
  (verify)

Pranlukast (brand name Onon, オノン) is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s montelukast (Singulair). It is widely used in Japan.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.[2]

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models [3].

References

  1. ^ a b Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma". Drug Metab Pharmacokinet. 21 (2): 133–9. doi:10.2133/dmpk.21.133. PMID 16702733. Archived from the original on 2008-09-17. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  2. ^ Singh, Rakesh Kumar; Tandon, Ruchi; Dastidar, Sunanda Ghosh; Ray, Abhijit (2013). "A review on leukotrienes and their receptors with reference to asthma". Journal of Asthma. 50 (9): 922–931. doi:10.3109/02770903.2013.823447. ISSN 0277-0903. PMID 23859232.
  3. ^ Mishra A; et al. (2018). "An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy". EMBO Molecular Medicine. 10 (4): e8038. doi:10.15252/emmm.201708038. {{cite journal}}: Explicit use of et al. in: |last= (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pranlukast&oldid=904940382"